These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 23587031)

  • 1. Cell-associated HIV RNA: a dynamic biomarker of viral persistence.
    Pasternak AO; Lukashov VV; Berkhout B
    Retrovirology; 2013 Apr; 10():41. PubMed ID: 23587031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-Associated HIV-1 Unspliced-to-Multiply-Spliced RNA Ratio at 12 Weeks of ART Predicts Immune Reconstitution on Therapy.
    Scherpenisse M; Kootstra NA; Bakker M; Berkhout B; Pasternak AO
    mBio; 2021 Mar; 12(2):. PubMed ID: 33688002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
    Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
    J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.
    Yukl SA; Shergill AK; Ho T; Killian M; Girling V; Epling L; Li P; Wong LK; Crouch P; Deeks SG; Havlir DV; McQuaid K; Sinclair E; Wong JK
    J Infect Dis; 2013 Oct; 208(8):1212-20. PubMed ID: 23852128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.
    Bull ME; Mitchell C; Soria J; Styrchak S; Williams-Wietzikoski C; Legard J; McKernan-Mullin J; Kraft K; Onchiri F; Stern J; Holte S; Ryan KJ; Acosta EP; La Rosa A; Coombs RW; Ticona E; Frenkel LM
    AIDS; 2018 Jul; 32(11):1389-1401. PubMed ID: 29683841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
    Amendola A; Sberna G; Forbici F; Abbate I; Lorenzini P; Pinnetti C; Antinori A; Capobianchi MR
    PLoS One; 2020; 15(2):e0228192. PubMed ID: 32023284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.
    Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test.
    Jagodzinski LL; Manak MM; Hack HR; Liu Y; Malia JA; Freeman J; Phanuphak N; de Souza M; Kroon ED; Colby DJ; Chomchey N; Lally MA; Michael NL; Ananworanich J; Peel SA;
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30842229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
    Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells.
    van Zyl GU; Bedison MA; van Rensburg AJ; Laughton B; Cotton MF; Mellors JW
    J Infect Dis; 2015 Jul; 212(1):39-43. PubMed ID: 25538273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.
    Pasternak AO; Grijsen ML; Wit FW; Bakker M; Jurriaans S; Prins JM; Berkhout B
    JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32097124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
    Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
    J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.
    Uprety P; Chadwick EG; Rainwater-Lovett K; Ziemniak C; Luzuriaga K; Capparelli EV; Yenokyan G; Persaud D
    Clin Infect Dis; 2015 Dec; 61(12):1862-70. PubMed ID: 26270687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART.
    Lombardi F; Belmonti S; Rapone L; Borghetti A; Ciccullo A; Gagliardini R; Baldin G; Montagnani F; Moschese D; Emiliozzi A; Rossetti B; De Luca A; Di Giambenedetto S
    J Clin Virol; 2018 Jun; 103():57-62. PubMed ID: 29656086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells.
    Althaus CL; Joos B; Perelson AS; Günthard HF
    PLoS Comput Biol; 2014 Oct; 10(10):e1003871. PubMed ID: 25340797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
    Marcelin AG; Tubiana R; Lambert-Niclot S; Lefebvre G; Dominguez S; Bonmarchand M; Vauthier-Brouzes D; Marguet F; Mousset-Simeon N; Peytavin G; Poirot C
    AIDS; 2008 Aug; 22(13):1677-9. PubMed ID: 18670231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.
    Burgard M; Boufassa F; Viard JP; Garrigue I; Ruffault A; Izopet J; Vabret A; Descamps D; Colson P; Seigneurin JM; Rouzioux C;
    AIDS; 2009 Oct; 23(16):2165-71. PubMed ID: 19657270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
    Chun TW; Justement JS; Murray D; Hallahan CW; Maenza J; Collier AC; Sheth PM; Kaul R; Ostrowski M; Moir S; Kovacs C; Fauci AS
    AIDS; 2010 Nov; 24(18):2803-8. PubMed ID: 20962613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood biomarkers of expressed and inducible HIV-1.
    Cillo AR; Hong F; Tsai A; Irrinki A; Kaur J; Sloan DD; Follen M; Geleziunas R; Cihlar T; Win SS; Murry JP; Mellors JW
    AIDS; 2018 Mar; 32(6):699-708. PubMed ID: 29334544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.